Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FPI-1848
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FPI-1848 is an investigational targeted alpha therapy (TAT) radiopharmaceutical developed by Fusion Pharmaceuticals (now a subsidiary of AstraZeneca). It consists of a targeting moiety specific for the Insulin-like Growth Factor 1 Receptor (IGF-1R) conjugated to the alpha-emitting radioisotope Actinium-225 (^225Ac) via Fusion's proprietary "Fast-Clear" linker technology. IGF-1R is frequently overexpressed in various solid tumors and plays a key role in tumor growth and survival. By targeting this receptor, FPI-1848 delivers high-energy alpha particles directly to the tumor microenvironment, causing lethal double-stranded DNA breaks in malignant cells while the Fast-Clear linker facilitates rapid systemic elimination of the non-bound drug to reduce radiation exposure to healthy tissues. It is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors.
- Other names
- 225Ac-FPI-1848
02
Targets
TEM-1 (TEM-1 beta-lactamase)
Beyond the preview
Go deeper on FPI-1848.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FPI-1848.